200 related articles for article (PubMed ID: 1326622)
1. Clocinnamox: a novel, systemically-active, irreversible opioid antagonist.
Comer SD; Burke TF; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1992 Sep; 262(3):1051-6. PubMed ID: 1326622
[TBL] [Abstract][Full Text] [Related]
2. Irreversible opioid antagonist effects of clocinnamox on opioid analgesia and mu receptor binding in mice.
Burke TF; Woods JH; Lewis JW; Medzihradsky F
J Pharmacol Exp Ther; 1994 Nov; 271(2):715-21. PubMed ID: 7965787
[TBL] [Abstract][Full Text] [Related]
3. Use of irreversible antagonists to determine the relative efficacy of mu-opioids in a pigeon drug discrimination procedure: comparison of beta-funaltrexamine and clocinnamox.
Barrett AC; Smith ES; Picker MJ
J Pharmacol Exp Ther; 2003 Jun; 305(3):1061-70. PubMed ID: 12649297
[TBL] [Abstract][Full Text] [Related]
4. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
[TBL] [Abstract][Full Text] [Related]
5. In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox.
Zernig G; Butelman ER; Lewis JW; Walker EA; Woods JH
J Pharmacol Exp Ther; 1994 Apr; 269(1):57-65. PubMed ID: 8169852
[TBL] [Abstract][Full Text] [Related]
6. Assessment of relative intrinsic activity of mu-opioid analgesics in vivo by using beta-funaltrexamine.
Adams JU; Paronis CA; Holtzman SG
J Pharmacol Exp Ther; 1990 Dec; 255(3):1027-32. PubMed ID: 2175793
[TBL] [Abstract][Full Text] [Related]
7. Clocinnamox antagonism of the antinociceptive effects of mu opioids in squirrel monkeys.
Pitts RC; Allen RM; Walker EA; Dykstra LA
J Pharmacol Exp Ther; 1998 Jun; 285(3):1197-206. PubMed ID: 9618423
[TBL] [Abstract][Full Text] [Related]
8. Methoclocinnamox: agonist and antagonist effects of a novel long-lasting opioid in rhesus monkeys.
Butelman ER; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1996 Nov; 279(2):934-8. PubMed ID: 8930202
[TBL] [Abstract][Full Text] [Related]
9. Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity.
McLaughlin JP; Hill KP; Jiang Q; Sebastian A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1999 Apr; 289(1):304-11. PubMed ID: 10087018
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological actions of a novel mixed opiate agonist/antagonist: naloxone benzoylhydrazone.
Gistrak MA; Paul D; Hahn EF; Pasternak GW
J Pharmacol Exp Ther; 1989 Nov; 251(2):469-76. PubMed ID: 2553921
[TBL] [Abstract][Full Text] [Related]
11. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice.
Kögel B; Christoph T; Strassburger W; Friderichs E
Eur J Pain; 2005 Oct; 9(5):599-611. PubMed ID: 16139189
[TBL] [Abstract][Full Text] [Related]
12. Morphine hyperalgesia in mice is unrelated to opioid activity, analgesia, or tolerance: evidence for multiple diverse hyperalgesic systems.
Juni A; Klein G; Kest B
Brain Res; 2006 Jan; 1070(1):35-44. PubMed ID: 16409995
[TBL] [Abstract][Full Text] [Related]
13. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
Baker AK; Meert TF
J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
[TBL] [Abstract][Full Text] [Related]
14. Evidence for the interaction of morphine with kappa and delta opioid receptors to induce analgesia in beta-funaltrexamine-treated mice.
Takemori AE; Portoghese PS
J Pharmacol Exp Ther; 1987 Oct; 243(1):91-4. PubMed ID: 2822908
[TBL] [Abstract][Full Text] [Related]
15. In vivo apparent pA2 analysis for naltrexone antagonism of discriminative stimulus and analgesic effects of opiate agonists in rats.
Walker EA; Makhay MM; House JD; Young AM
J Pharmacol Exp Ther; 1994 Nov; 271(2):959-68. PubMed ID: 7965818
[TBL] [Abstract][Full Text] [Related]
16. Clocinnamox distinguishes opioid agonists according to relative efficacy in normal and morphine-treated rats trained to discriminate morphine.
Walker EA; Young AM
J Pharmacol Exp Ther; 2002 Jul; 302(1):101-10. PubMed ID: 12065706
[TBL] [Abstract][Full Text] [Related]
17. Naltrexone antagonizes the analgesic and immunosuppressive effects of morphine in mice.
Carr DJ; Gerak LR; France CP
J Pharmacol Exp Ther; 1994 May; 269(2):693-8. PubMed ID: 8182537
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of dose-dependent antagonism by beta-funaltrexamine of the antinociceptive effects of intrathecal mu agonists.
Mjanger E; Yaksh TL
J Pharmacol Exp Ther; 1991 Aug; 258(2):544-50. PubMed ID: 1650833
[TBL] [Abstract][Full Text] [Related]
19. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay.
Sterious SN; Walker EA
J Pharmacol Exp Ther; 2003 Jan; 304(1):301-9. PubMed ID: 12490605
[TBL] [Abstract][Full Text] [Related]
20. Mirfentanil: pharmacological profile of a novel fentanyl derivative with opioid and nonopioid effects.
France CP; Winger G; Medzihradsky F; Seggel MR; Rice KC; Woods JH
J Pharmacol Exp Ther; 1991 Aug; 258(2):502-10. PubMed ID: 1650830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]